Moritz Hilbrandt

Outcome of First-Line Treatment With Pembrolizumab According to KRAS/TP53 Mutational Status for Nonsquamous Programmed Death-Ligand 1–High (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer

Philip Bischoff, Martin Reck, Tobias R. Overbeck et al. · Journal of Thoracic Oncology · 2023 · 48 citations · Full text

Medicine, Immunology, Oncology +17

Clinical and virological characteristics of hospitalised COVID-19 patients in a German tertiary care centre during the first wave of the SARS-CoV-2 pandemic: a prospective observational study

Charlotte Thibeault, Barbara Mühlemann, Elisa T. Helbig et al. · Infection · 2021 · 31 citations · Full text

Engineering, Infectious Diseases, Hospital Medicine +13

Protective Function of STAT3 in CVB3-Induced Myocarditis

Diana Lindner, Moritz Hilbrandt, Katharina Marggraf et al. · Cardiology Research and Practice · 2012 · 26 citations · Full text

Veterinary Medicine, Cardiology, Pathobiology +17

First-line immunotherapy for lung cancer with MET exon 14 skipping and the relevance of TP53 mutations

Miriam Blasi, Jonas Kuon, H Lüders et al. · European Journal of Cancer · 2024 · 20 citations · Full text

Medicine, Oncology, Pharmacology +15

Management, risk factors and prognostic impact of checkpoint-inhibitor pneumonitis (CIP) in lung cancer – A multicenter observational analysis

Nikolaj Frost, Kristina Unger, Torsten Blum et al. · Lung Cancer · 2023 · 16 citations

Medicine, Oncology, Pharmacotherapy +17